U.S. markets closed

Bio-Path Holdings, Inc. (BPTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.1800-0.3100 (-8.88%)
At close: 04:00PM EDT
3.2000 +0.02 (+0.63%)
After hours: 04:10PM EDT

Bio-Path Holdings, Inc.

4710 Bellaire Boulevard
Suite 210
Bellaire, TX 77401
United States
832 742 1357

Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter H. Nielsen MBACo-Founder, Chairman, CEO, Pres, CFO & Treasurer680.18kN/A1949
Mr. Douglas P. MorrisCo-Founder, Director of Investor Relations, Sec. & Director68.47kN/A1956
Mr. Anthony PriceSr. VP of Fin., Accounting & Admin.N/AN/AN/A
Dr. Ana Tari Ashizawa Ph.D., MBASr. VP of Research, Devel. & Clinical DesignN/AN/AN/A
Dr. Alan MacKenzie Ph.D.ConsultantN/AN/AN/A
Dr. Thomas A. Walker Ph.D.ConsultantN/AN/AN/A
Dr. Jeffery Lancet M.D.ConsultantN/AN/AN/A
Ms. Victoria Lake RacRegulatory ConsultantN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Corporate Governance

Bio-Path Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.